BioCentury | Nov 18, 2020
Emerging Company Profile

InterVenn: liquid biopsy diagnostics based on glycoproteins

...Stanford University professor, and Carlito Lebrilla, a University of California Davis...
BioCentury | Mar 14, 2020
Emerging Company Profile

Indapta harnesses natural NK cell subset to create allogeneic cancer therapy

...an assistant professor. Kim is now an associate professor of medical microbiology and immunology at University of California Davis...
...Martell, John Sunwoo and Sungjin Kim University collaborators: Stanford University, University of California San Francisco, University of California Davis...
BioCentury | Dec 19, 2019
Preclinical News

Dec. 19 Preclinical Quick Takes: First recipients of AACR-MPM Capital impact fund grants revealed; plus pre-conception protection with NIH’s Zika vaccine, Vivet

...in three mouse models of asthma. BioCentury Staff American Association for Cancer Research MPM Capital Vivet Therapeutics GlaxoSmithKline plc University of Zurich University of California Davis NIH ContraFect...
BioCentury | Jul 18, 2019
Finance

As funding dwindles, CIRM believes goals within reach

...to treat cystinosis, and a treatment for spina bifida developed by Diana Farmer at the University of California Davis....
...jCyte Inc., Newport Beach, Calif. Orchard Therapeutics plc (NASDAQ:ORTX), London, U.K. Stanford University, Stanford, Calif. University of California Davis...
BioCentury | Mar 4, 2019
Distillery Therapeutics

Inhibiting soluble epoxide hydrolase for renal damage

...Natl. Acad. Sci. USA ; published online Feb. 25, 2019 doi:10.1073/pnas.1815746116 CONTACT: Bruce D. Hammock, University of California Davis...
...email: bdhammock@ucdavis.edu CONTACT: Jun-Yan Liu, Tongji University School of Medicine, Shanghai, China email: jyliu@tongji.edu.cn Claire Quang Tongji University University of California Davis Epoxide...
BioCentury | Dec 4, 2018
Distillery Therapeutics

Cancer

...University of California Davis, Davis, Calif. email: acgao@ucdavis.edu Claire Quang Xtandi, enzalutamide (mdv3100, p-INN) Zytiga (Brand), CB7630 (Compound #), abiraterone acetate (Generic) University of California Davis Heat...
BioCentury | Sep 26, 2018
Distillery Techniques

Drug delivery

...published online Sept. 7, 2018 doi:10.1038/s41467-018-06093-5 CONTACT: Yuanpei Li, University of California Davis, Davis, Calif. email: lypli@ucdavis.edu Jaime De Leon University of California Davis Cancer...
BioCentury | Nov 27, 2017
Distillery Therapeutics

Renal

...bdhammock@ucdavis.edu CONTACT: Jun-Yan Liu, Tongji University School of Medicine, Shanghai, China email: jyliu@tongji.edu.cn Hongjiang Li EicOsis LLC Tongji University University of California Davis Epoxide...
BioCentury | Oct 12, 2017
Finance

IRDiRC dreams bigger

...nine recipient institutions that will share $100 million over the next five years. Centers include University of California Davis...
BioCentury | Sep 28, 2017
Company News

CIRM names CEO, funds additional clinics and trials

...Alpha Stem Cell Clinics -- medical centers which perform stem cell trials -- at the University of California Davis...
...the cells. Chris Lieu PEC-Direct VC-02 California Institute for Regenerative Medicine (CIRM) City of Hope Forty Seven Inc. Humacyte Inc. Nohla Therapeutics Inc. Stanford University University of California Davis University...
Items per page:
1 - 10 of 117
BioCentury | Nov 18, 2020
Emerging Company Profile

InterVenn: liquid biopsy diagnostics based on glycoproteins

...Stanford University professor, and Carlito Lebrilla, a University of California Davis...
BioCentury | Mar 14, 2020
Emerging Company Profile

Indapta harnesses natural NK cell subset to create allogeneic cancer therapy

...an assistant professor. Kim is now an associate professor of medical microbiology and immunology at University of California Davis...
...Martell, John Sunwoo and Sungjin Kim University collaborators: Stanford University, University of California San Francisco, University of California Davis...
BioCentury | Dec 19, 2019
Preclinical News

Dec. 19 Preclinical Quick Takes: First recipients of AACR-MPM Capital impact fund grants revealed; plus pre-conception protection with NIH’s Zika vaccine, Vivet

...in three mouse models of asthma. BioCentury Staff American Association for Cancer Research MPM Capital Vivet Therapeutics GlaxoSmithKline plc University of Zurich University of California Davis NIH ContraFect...
BioCentury | Jul 18, 2019
Finance

As funding dwindles, CIRM believes goals within reach

...to treat cystinosis, and a treatment for spina bifida developed by Diana Farmer at the University of California Davis....
...jCyte Inc., Newport Beach, Calif. Orchard Therapeutics plc (NASDAQ:ORTX), London, U.K. Stanford University, Stanford, Calif. University of California Davis...
BioCentury | Mar 4, 2019
Distillery Therapeutics

Inhibiting soluble epoxide hydrolase for renal damage

...Natl. Acad. Sci. USA ; published online Feb. 25, 2019 doi:10.1073/pnas.1815746116 CONTACT: Bruce D. Hammock, University of California Davis...
...email: bdhammock@ucdavis.edu CONTACT: Jun-Yan Liu, Tongji University School of Medicine, Shanghai, China email: jyliu@tongji.edu.cn Claire Quang Tongji University University of California Davis Epoxide...
BioCentury | Dec 4, 2018
Distillery Therapeutics

Cancer

...University of California Davis, Davis, Calif. email: acgao@ucdavis.edu Claire Quang Xtandi, enzalutamide (mdv3100, p-INN) Zytiga (Brand), CB7630 (Compound #), abiraterone acetate (Generic) University of California Davis Heat...
BioCentury | Sep 26, 2018
Distillery Techniques

Drug delivery

...published online Sept. 7, 2018 doi:10.1038/s41467-018-06093-5 CONTACT: Yuanpei Li, University of California Davis, Davis, Calif. email: lypli@ucdavis.edu Jaime De Leon University of California Davis Cancer...
BioCentury | Nov 27, 2017
Distillery Therapeutics

Renal

...bdhammock@ucdavis.edu CONTACT: Jun-Yan Liu, Tongji University School of Medicine, Shanghai, China email: jyliu@tongji.edu.cn Hongjiang Li EicOsis LLC Tongji University University of California Davis Epoxide...
BioCentury | Oct 12, 2017
Finance

IRDiRC dreams bigger

...nine recipient institutions that will share $100 million over the next five years. Centers include University of California Davis...
BioCentury | Sep 28, 2017
Company News

CIRM names CEO, funds additional clinics and trials

...Alpha Stem Cell Clinics -- medical centers which perform stem cell trials -- at the University of California Davis...
...the cells. Chris Lieu PEC-Direct VC-02 California Institute for Regenerative Medicine (CIRM) City of Hope Forty Seven Inc. Humacyte Inc. Nohla Therapeutics Inc. Stanford University University of California Davis University...
Items per page:
1 - 10 of 117